GlobeNewswire by notified

Indegene and SynPhNe join hands to bring relief to stroke and TBI victims worldwide

Share

PRINCETON, N.J. and SINGAPORE, May 16, 2023 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced today that it is joining hands with SynPhNe, to bring their Synergistic Physio-Neuro Platform to market.

SynPhNe has developed the world’s first connected wearable solution that trains brain and muscle in one system. It is designed to help stroke survivors and patients with disabilities recover and lead more independent lives. This device is backed by ten years of clinical studies and provides a wide range of care programs that can address the key challenges of rehabilitation and recovery from neurological conditions including stroke and traumatic brain injuries (TBI), learning disabilities, the effects of aging, chronic stress, and pain.

SynPhNe uses a real-time neuroplasticity training model to help the body and brain recover function together. Real-time, synchronized EEG and EMG signals are captured during tasks and activities to create a self-correcting learning loop, making it possible to self-administer physical therapy, occupational therapy, and neuro therapy protocols at home, after initial training with a therapist.

Both the stroke and TBI markets are growing rapidly. Currently, the stroke management industry is estimated to be over $37 billion, and it is projected to reach more than $59 billion by 20321. More than 6 million people worldwide each year are pegged as stroke survivors. The traumatic brain injury market is also growing with more than 69 million people worldwide sustaining a TBI each year2.

Sabi Bivas, President of SynPhNe Health, Inc., said “More people are being impacted by neurological conditions each year. To help them get better access to effective treatment, we are excited to work with Indegene to bring our treatment option to the market. Indegene’s focus on technology and providing future-ready healthcare aligns with our mission. We will leverage their modern commercialization model to try and bring relief to many more people around the world suffering from strokes, TBIs, and other neurological conditions.”

Timothy Moore, Senior Vice President, Emerging Biotech and Key Accounts, Indegene, said, “We are excited to join hands with SynPhNe to support their early commercialization and bring this device to market. We will use our modern go-to-market model to drive pricing strategy and develop a strategic launch plan that coordinates education and marketing efforts based on our deep expertise in market research and brand planning.”

About SynPhNe

SynPhNe™ is a Singapore-based company that has designed the world’s first wearable solution which trains brain and muscle in one system. It is designed to help restore movement, cognition, and function in patients after stroke and other neurology-related disorders. Their device gives patients a platform to take charge of their own rehabilitation in real-time. Whether a patient is coping with a disability from stroke or experiencing the first signs of aging, SynPhNe is an award-winning technology that has empowered people worldwide to live more fulfilled lives. To learn more, please visit www.synphne.com

About Indegene

We are a digital-first, life sciences commercialization company. We help biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. We bring together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions. These aim to deliver, amongst other outcomes, a personalized, scalable and omnichannel experience for patients and physicians. It’s what drives our team and our purpose to enable healthcare organizations to be future ready. To learn more, please visit www.indegene.com

For media inquiries, please contact:

Sabi Bivas | Sabi@synphne.com
Yadunandan K V | yadunandan.kv@indegene.com

1Stroke Management Market Share Statistics Report 2023-2032 (gminsights.com)

2Traumatic brain injury: Statistical data on recovery and mortality (tbi.com)

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Bombardier Reports Significant Backlog Growth on 1.6 Unit Book-to-Bill, Expanded Margins and Service Revenues Increase in First Quarter of 202425.4.2024 12:30:00 CEST | Press release

Revenues of $1.3 billion for the first quarter reflect 13% year-over-year aftermarket growth and 20 aircraft deliveries, in line with production plan and full year delivery guidance of 150 to 155 aircraft.Adjusted EBITDA(1) of $205 million for the first quarter. Adjusted EBITDA margin(2) rose 140 bps year-over-year to 16%. Reported EBIT for the first quarter was $144 million. Adjusted EPS(2) positive at $0.36 for the first quarter, with diluted EPS(3) at $1.02. Free cash flow usage(1) of $387 million reflects expected working capital build in inventories supporting production ramp-up. Reported cash flow usage from operating activities and net additions to PP&E and intangible assets were at $343 million and $44 million respectively.​Focus on deleveraging continued with $100 million debt redemption announced on March 14th and closed in April; available liquidity(1) remained strong at $1.4 billion. Cash and cash equivalents were $1.2 billion as at March 31, 2024. First quarter unit order

Resolutions of Huhtamäki Oyj’s Annual General Meeting of Shareholders25.4.2024 12:30:00 CEST | Press release

HUHTAMÄKI OYJ STOCK EXCHANGE RELEASE 25.4.2024 AT 13:30 EEST Resolutions of Huhtamäki Oyj’s Annual General Meeting of Shareholders Huhtamäki Oyj’s Annual General Meeting of Shareholders was held in Helsinki on April 25, 2024. The meeting adopted the Annual Accounts including the Consolidated Annual Accounts for 2023, discharged the members of the Company’s Board of Directors and the CEO from liability, and approved all proposals made to the Annual General Meeting by the Board of Directors and the Shareholders’ Nomination Board. The Annual General Meeting also approved the Remuneration Report for the Company’s Governing Bodies presented to it. Dividend The Annual General Meeting resolved that an aggregate dividend of EUR 1.05 per share be paid based on the balance sheet adopted for the financial period ended on December 31, 2023. The dividend will be paid in two instalments. The first dividend instalment, EUR 0.53 per share, will be paid to shareholders registered in the Company’s regis

AS Tallink Grupp Investor Webinar introducing the results of the Q1 202425.4.2024 12:30:00 CEST | Press release

On 25 April 2024 AS Tallink Grupp held an investor webinar where Paavo Nõgene, the Chairman of the Management Board, and Harri Hanschmidt and Margus Schults, the members of the Management Board introduced the results of the first quarter of 2024. AS Tallink Grupp would like to thank all the participants. The webinar presentation is enclosed and the webinar recording is available at www.tallink.com/investors/webinars. Anneli Simm Investor Relations Manager AS Tallink Grupp Sadama 5 10111 Tallinn, Estonia E-mail anneli.simm@tallink.ee Attachment AS Tallink Grupp Q1 2024 Webinar Presentation

Passing of Columbus A/S’ Annual General Meeting and subsequent constitution of the Board of Directors25.4.2024 12:21:35 CEST | Press release

Company announcement no. 12/2024 At Columbus A/S’ Annual General Meeting held on 25 April 2024, all proposals set out in the agenda were adopted, including the following; 1. The General Meeting took note of the Board of Directors’ report. 2. The Annual Report for 2023 was approved. 3. The Board of Directors’ proposal regarding distribution of profit was adopted, including payment of an ordinary dividend to the shareholders of DKK 0.125 per share of DKK 1.25 (nom), amounting to a total dividend of DKK 16,159,533. 4. The Remuneration Report for 2023 was approved in the indicative ballot. 5. The General Meeting authorized the Board of Directors for a period of 18 months from the date of the General Meeting to acquire up to 10 per cent of the Company’s share capital against payment which shall not deviate more than 10 per cent up or downwards from the latest listed price of the shares at Nasdaq Copenhagen prior to the acquisition. 6. Ib Kunøe, Peter Skov Hansen, Sven Madsen, Karina Kirk an

Nexstim Plc: Managers’ Transactions, Hildén25.4.2024 12:15:00 CEST | Press release

Company Announcement, Helsinki, 25 April 2024 at 1:15 PM (EEST) Nexstim Plc: Managers’ Transactions, Hildén Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers’ transactions as follows: Person subject to the notification requirement Name: Timo Hildén Position: Member of the Board/Deputy member Issuer: Nexstim Oyj LEI: 743700S7ZI0LNMHZ6Y27 Notification type: INITIAL NOTIFICATION Reference number: 59502/4/4 ____________________________________________ Transaction date: 2024-04-23 Outside a trading venue Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT Name of the instrument: 2024H Nature of transaction: ACCEPTANCE OF A STOCK OPTION (X) Linked to stock option programme Transaction details (1): Volume: 8500 Unit price: 0 EUR Aggregated transactions (1): Volume: 8500 Volume weighted average price: 0 EUR Further information is available on the website www.nexstim.com, or by contacting: Mikko Karvinen, CEO +358 50 326 4101 mikko.karvinen@nexstim.com

HiddenA line styled icon from Orion Icon Library.Eye